Hundreds of male and female fibromyalgia patients, ages 18 to 70, will be recruited soon at 58 U.S. sites for participation in a major 11-week trial of two differently-acting prescription drugs taken in combination. Formal title: “Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia” – ClinicalTrials.gov Identifier NCT00797797. (Results will be compared with results for a cohort of patients taking pregabalin only.)
Each of the two drugs – pregabalin (Lyrica™) and milnacipran (Savella™) – has been approved by the FDA for treatment of fibromyalgia symptoms. Savella, just approved on January 14, 2009, will not be widely available in US pharmacies until March.
For more information and to review a list of the 58 trial sites – so far identified only by state/town and zip code – go to the ClinicalTrials.gov listing for the trial at http://www.clinicaltrials.gov/ct2/show/NCT00797797
To Contact the Trial Coordinators:
Sandra Beaird, PhD
1-800-678-1605 ext 66297
The trial is sponsored by Forest Laboratories.